FTSE 100 news / Companies and sectors / GSK / 16 October 2026
GSK (GSK): news on Friday 16 October 2026
+0.8 neutral
Coverage was split between plans to cut up to 1,217 jobs in Belgium, with union blockades, and positive items such as an $800M US manufacturing hub, executive share purchases and a share price gain. The job cut and labour dispute stories offset the investment and insider buying news, leaving a broadly neutral tone.
What drove it
- Belgian job cuts
- US manufacturing investment
- executive share purchases
The 16 stories
- +9.2 GSK Plans $800M Biopharma Manufacturing Hub in Pennsylvania
$800M US manufacturing investment shows expansion. - −8.3 Trade unions continue blocking GSK work sites following mass job cuts
Union blockades of work sites after mass job cuts. - +7.5 GSK shares gain almost 2% after CEO and CFO increase holdings and technical momentum builds
Shares up almost 2% after CEO and CFO buy. - +7.0 GSK (LSE:GSK) Could Be 14% Below Fair Value As R and D Spending Rises
Valuation analysis suggests shares undervalued despite rising R&D spending. - +5.8 Three executives acquire GSK (NYSE: GSK) depositary shares at $46.95 each.
Executives buying shares signals insider confidence. - +5.0 GSK Stock Gains 2.89% on Thursday: Full Details
Share price gain of 2.89% in a day. - +5.0 GSK begins Oxford colitis trial: RBC keeps target for GSK stock - ad-hoc-news.de
Begins colitis trial; RBC keeps target. - −5.0 GSK Layoffs: Pharma Giant to Cut Up to 1,217 Jobs in Belgium Restructuring
Layoffs of up to 1,217 jobs in Belgium. - −4.7 GSK plans up to 1,217 job cuts in Belgium as part of cost-savings drive
Up to 1,217 Belgian job cuts in cost-savings drive. - −4.2 GSK to cut jobs in Belgium as it begins restructuring
Belgian restructuring involving job cuts. - +3.7 GSK Korea Marks 40th Anniversary With Community Health Programs
Korean subsidiary marks anniversary with community programmes. - +3.3 Greater Philadelphia Life Sciences News: Agilent’s Philly Acquisition, GSK’s Big Bet & More
Regional roundup mentioning GSK's big investment bet. - −2.5 Is GSK cutting jobs to fund R&D?
Questions job cuts linked to funding R&D; mildly negative framing. - +1.3 Better Dividend Stock: Pfizer vs. GSK
Dividend comparison with Pfizer; mildly informative, balanced. - +0.3 GSK plc : UBS remains Neutral
UBS maintains Neutral rating. - 0.0 GSK trades flat as range-bound trading dominates near key resistance levels
Shares flat in range-bound trading.
GSK: every day · Pharma and healthcare on 16 October 2026 · FTSE 100 overview for the day